The first-in-human study showed THT can safely prime and shrink tumours in immunotherapy-resistant melanoma patients. The next question is what happens when THT is combined with immunotherapy drugs. Sona has announced two studies to answer that question, one for patients who have already exhausted their treatment options, and one for patients at the beginning of their melanoma journey. Together, IGNITE-THT and PRIME-THT represent the clearest picture yet of where this therapy is headed. Hear directly from management on Thursday, May 7th at 1pm ET. The session will conclude with a live Q&A.